XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The company has raised US$4.5 million in funding for its AI operating system
PhytoSquene now available for clinical and commercial use
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Subscribe To Our Newsletter & Stay Updated
